Isatuximab
Isatuximab 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Multiple Myeloma。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
24 项
全球在招研究
5 项
已进入 III/IV 期
17 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- Canadian Cancer Trials Group
- M.D. Anderson Cancer Center
- PETHEMA Foundation
- Multiple Myeloma Research Consortium
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
- Natalie Callander
- Institute of Hematology & Blood Diseases Hospital, China
- Pack Health
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
西班牙、美国、意大利、中国、法国、澳大利亚、Brazil、加拿大、丹麦、德国、日本、Poland
正在招募患者的 Isatuximab 研究
Efficacy and Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Multiple Myeloma (GEM-AnitoFIRST)
II 期招募中西班牙NCT07045909Horizon Two: HR NDMM (MMRC-100)
II 期招募中美国NCT07053436Efficacy of Isatuximab-based Regimens in Relapsed/Refractory Multiple Myeloma With 1q21+
不适用招募中意大利NCT06874530Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients
II 期招募中美国NCT05776979Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma
I 期 / II 期招募中美国NCT07479979Phase I/II Study of Anti-CD38 Monoclonal Antibody in Refractory Severe Aplastic Anemia
I 期 / II 期招募中中国NCT07714512Real World Insights During Treatment for Relapsed/Refractory Multiple Myeloma with Isatuximab
不适用招募中美国NCT05053607A 3-cohort Randomized Study Evaluating the Role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Frontline Therapy of Adults With Acute Lymphoblastic Leukemia
II 期 / III 期招募中法国NCT06860269Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
III 期招募中美国澳大利亚Brazil加拿大NCT07764978CM336 Plus Isatuximab for Newly Diagnosed Multiple Myeloma With Renal Impairment
II 期招募中中国NCT07585760Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
II 期招募中美国NCT05145400IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
I 期 / II 期招募中美国NCT06119685Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients
II 期 / III 期招募中德国NCT05665140A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma
II 期招募中美国NCT06115135Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients With Renal Insufficiency
II 期招募中美国NCT04240054Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
I 期 / II 期招募中美国澳大利亚法国德国NCT04643002A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
I 期招募中美国法国GreeceIsraelNCT05137054ELISA in Relapsed/Refractory MM
II 期招募中美国NCT06832865Study Comparing Therapy for Advanced Relapsed/Refractory Multiple Myeloma With and Without Dexamethasone
III 期招募中法国NCT06561854Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma
II 期招募中美国NCT05922501Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients
不适用招募中中国NCT07663253D2 - Isa-Iber-VD Induction, Followed by Risk & Response Adapted Consolidation & Maintenance, in Transplant-Eligible NDMM
III 期招募中美国NCT07624513Clinical Trial for Autologus NK Cells Alone or in Combination With Isatuximab as Maintenance for Multiple Myeloma
II 期招募中瑞典NCT04558931Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients
II 期招募中加拿大NCT05272826
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。